Athena Cristina Ribigan

Dr. Athena Cristina Ribigan

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
Alexandru SoriciAlexandru Sorici
Alexandru Sorici
LBLidia Bajenaru
Lidia Bajenaru
Irina Georgiana MocanuIrina Georgiana Mocanu
Irina Georgiana Mocanu
Adina Adina FloreaAdina Adina Florea
Adina Adina Florea
Panagiotis TsakanikasPanagiotis Tsakanikas
Panagiotis Tsakanikas
Anastasia BougeaAnastasia Bougea
Anastasia Bougea
(1) Objective: We explore the predictive power of a novel stream of patient data, combining wearable devices and patient reported outcomes (PROs), using an AI-first approach to classify the health status of Parkinson’s disease (PD), multiple sclerosis (MS) and stroke patients (collectively named PMSS). (2) Background: Recent studies acknowledge the burden of neurological disorders on patients and on the healthcare systems managing them. To address this, effort is invested in the digital transformation of health provisioning for PMSS patients. (3) Methods: We introduce the data collection journey within the ALAMEDA project, which continuously collects PRO data for a year through mobile applications and supplements them with data from minimally intrusive wearable devices (accelerometer bracelet, IMU sensor belt, ground force measuring insoles, and sleep mattress) worn for 1–2 weeks at each milestone. We present the data collection schedule and its feasibility, the mapping of medical predictor variables to wearable device capabilities and mobile application functionality. (4) Results: A novel combination of wearable devices and smartphone applications required for the desired analysis of motor, sleep, emotional and quality-of-life outcomes is introduced. AI-first analysis methods are presented that aim to uncover the prediction capability of diverse longitudinal and cross-sectional setups (in terms of standard medical test targets). Mobile application development and usage schedule facilitates the retention of patient engagement and compliance with the study protocol.

21 March 2025 in IEEE Internet of Things Journal
Verified
Journal Article
Closed access
SAShehzad Ali
Shehzad Ali
MSMuhammad Sajjad
Muhammad Sajjad
ILIk Hyun Lee
Ik Hyun Lee
Faouzi Alaya CheikhFaouzi Alaya Cheikh
Faouzi Alaya Cheikh
ARAthena Cristina Ribigan
Athena Cristina Ribigan
Khan MuhammadKhan Muhammad
Khan Muhammad
Facial emotion recognition (FER) plays a critical role in understanding human behavior, especially for individuals suffering from neurological disorders (NDs) like Parkinson’s disease (PD), Multiple Sclerosis (MS), and Stroke. Early and accurate detection of emotions is crucial for both the diagnosis of associated mood disorders and continuous monitoring. However, traditional methods often fall short in providing noninvasive, real-time solutions and lack the clinical expertise necessary to identify the specific emotion types associated with each ND category. In response, this research conducted under the ALAMEDA consortium presents an Internet of Things-based FER AI Toolkit designed to enhance early diagnosis and treatment for brain diseases. The toolkit is in line with the consortium’s clinical guidelines and provides a personalized, patient-focused solution that supports the goals of Industry 5.0 in healthcare. In line with Industry 5.0 principles, the FER AI Toolkit uses edge devices to collect real-time facial data while deep learning models running on cloud servers process this data. The recognized emotions are uploaded to the Semantic Knowledge Graph (SemKG) server. This allows healthcare professionals to make informed decisions based on real-time data. Additionally, the toolkit integrates seamlessly with key components of the ALAMEDA, including the Identity Authentication Manager (IAM) for secure access and the ALAMEDA Innovation Hub (AIH) for efficient resource management. By offering continuous and personalized healthcare insights, the FER AI Toolkit helps bridge the gap between diagnosis and patient well-being, ultimately advancing healthcare systems. Training materials and video demonstrations are available at https://drive.google.com/drive/folders/1-iUz7FE2IrKHt5nMl3oGjsrCtk7Ps2bM?usp=sharing for further learning.

19 June 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
LBLidia Bajenaru
Lidia Bajenaru
Alexandru SoriciAlexandru Sorici
Alexandru Sorici
Irina Georgiana MocanuIrina Georgiana Mocanu
Irina Georgiana Mocanu
Adina Adina FloreaAdina Adina Florea
Adina Adina Florea
FAFlorina Anca Antochi
Florina Anca Antochi
ARAthena Cristina Ribigan
Athena Cristina Ribigan
Stroke is one of the leading causes of disability and death worldwide, a severe medical condition for which new solutions for prevention, monitoring, and adequate treatment are needed. This paper proposes a SDM framework for the development of innovative and effective solutions based on artificial intelligence in the rehabilitation of stroke patients by empowering patients to make decisions about the use of devices and applications developed in the European project ALAMEDA. To develop a predictive tool for improving disability in stroke patients, key aspects of stroke patient data collection journeys, monitored health parameters, and specific variables covering motor, physical, emotional, cognitive, and sleep status are presented. The proposed SDM model involved the training and consultation of patients, medical staff, carers, and representatives under the name of the Local Community Group. Consultation with LCG members, consists of 11 representative people, physicians, nurses, patients and caregivers, which led to the definition of a methodological framework to investigate the key aspects of monitoring the patient data collection journey for the stroke pilot, and a specific questionnaire to collect stroke patient requirements and preferences. A set of general and specific guidelines specifying the principles by which patients decide to use wearable sensing devices and specific applications resulted from the analysis of the data collected using the questionnaire. The preferences and recommendations collected from LCG members have already been implemented in this stage of ALAMEDA system design and development.

23 December 2021 in Medicine
Verified
Journal Article
Open access
IBIonuţ-Flavius Bratu
Ionuţ-Flavius Bratu
ARAthena Cristina Ribigan
Athena Cristina Ribigan
SMSorina Mihailă-Bâldea
Sorina Mihailă-Bâldea
RBRaluca Badea
Raluca Badea
DSDaniela Stefan
Daniela Stefan
FAFlorina Antochi
Florina Antochi
Rationale: Systemic lupus erythematosus (SLE) is characterized by numerous immunological abnormalities that lead to multiorgan involvement. Central and peripheral nervous system manifestations are present in 8% to 92% of the cases of SLE. Furthermore, there have been reported cases of secondary autoimmune myelofibrosis associated with SLE. Patient concerns: We present the case of a 64-year-old female who was transferred from the Cardiology Department, where she was admitted for pericardial-pleural-peritoneal effusion after being discharged from another hospital following the resolution of a febrile episode. During hospitalization, she presented multiple oculomotor nerves palsies and weakness in the lower limbs. Serial cerebral magnetic resonance imaging (MRI) revealed extensive cerebral venous thrombosis. Nerve conduction studies showed sensory-motor axonal polyneuropathy. Thoracic MRI revealed a rare finding in patients with SLE – lytic lesions. Diagnoses: Extensive clinical, imaging, blood, and urine tests were performed. The patient exhibited pancytopenia, elevated inflammatory markers, hyperhomocysteinemia, mild hypoproteinemia, and severe proteinuria. The Hematology consultation ascertained that the peripheral blood smear and the bone marrow aspiration showed no alterations suggestive for a primary hematological disease and the thoracic vertebral-medullary MRI changes had a very low probability of representing osteolytic lesions in the context of plasma cells dyscrasia, but could not exclude their being result of a secondary autoimmune myelofibrosis. Immunology blood tests highlighted the presence of antinuclear antibodies and lupus anticoagulants. In this context, the Rheumatology consultation established the diagnosis of SLE with multiple complications. Interventions: The patient received treatment with cyclophosphamide. Outcomes: The ocular motricity problems and the paraparesis showed improvement. However, 1 week later, the patient developed weakness, dyspnea, and right lower quadrant abdominal pain. The abdominal-pelvic computed tomography scan indicated an acute right retroperitoneal hematoma with active bleeding for which she underwent arterial embolization of the spinal lumbar arteries with optimal result, but she died a few days later. Lessons: We chose to present this case in order to highlight the importance of interdisciplinarity in diagnosing and managing patients with SLE and multiorgan ailments, especially when faced with rare constellations of complications such as extensive cerebral venous thrombosis and osseous lytic lesions caused by secondary autoimmune myelofibrosis.

18 December 2021 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
ADAndreea Dragusin
Andreea Dragusin
NGNicolae Grecu
Nicolae Grecu
ARAthena Cristina Ribigan
Athena Cristina Ribigan
RBRaluca Stefania Badea
Raluca Stefania Badea
ETElena Oana Terecoasa
Elena Oana Terecoasa
CTCristina Tiu
Cristina Tiu
Introduction Myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission, and its hallmark is fluctuating muscular weakness affecting the ocular, bulbar, respiratory, or limb muscles. Our objective is to highlight the difficulties encountered in diagnosing this disorder in patients lacking this characteristic phenomenon. Methods Three cases of patients presenting with progressive weakness of bulbar and ocular muscles, in whom a lack of fluctuation delayed the diagnosis of myasthenia gravis, are described. Results Amyotrophic lateral sclerosis was considered in two of the patients, while cavernous sinus thrombosis was initially diagnosed in the third. Electrodiagnostic, pharmacologic, and serologic testing ultimately established the diagnosis of myasthenia gravis. Conclusion While the typical clinical pattern of myasthenia gravis is well known and easily recognizable, there are cases when the diagnosis, and thus the treatment, is delayed because of low or absent fluctuation of symptoms. The acknowledgment of this probably underestimated presentation is important for expeditious management.

13 March 2022 in The American Journal of Emergency Medicine
Verified
Journal Article
Open access
PIPatricia Ioan
Patricia Ioan
ARAthena Cristina Ribigan
Athena Cristina Ribigan
OROctaviana Rusu
Octaviana Rusu
IBIonut Flavius Bratu
Ionut Flavius Bratu
RBRaluca Stefania Badea
Raluca Stefania Badea
FAFlorina Antochi
Florina Antochi
Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) that causes Coronavirus Disease 2019 (COVID-19) may determine a series of neurological complications directly, by invasion of the nervous system or indirectly, secondary to systemic organ failure. Posterior reversible encephalopathy syndrome (PRES) represents a clinical and radiological neurological entity involving predominantly the occipital lobes. PRES was observed in patients receiving cytotoxic drugs, patients suffering from infectious diseases and sepsis, hypertensive emergencies and eclampsia, renal or autoimmune diseases. As more infectious SARS-COV-2 variants are now dominant in most of the Europe, an increasing number of patients is presenting to the Emergency Department. Case report of a 38-year-old patient, with previous exposure to SARS-COV-2 presented to the Emergency Department (ED) with generalized tonic-clonic seizures, dyspnea, cortical blindness and aphasia. The patient had been exhibiting fever, cough and shortness of breath in the previous 10 days. He had no relevant medical history and was receiving antibiotics and corticosteroids as prescribed by his general practitioner. Laboratory findings together with the thoracic computed tomography scan were consistent with the diagnosis of severe SARS-COV-2 pneumonia. The cerebral MRI scans showed bilateral T2-weighted/FLAIR hyperintensities that were suggestive for PRES. The patient was diagnosed with COVID-19 complicated with PRES. He received adequate treatment and the symptoms resolved in 48 h. This is a rare and interesting case of a patient with PRES and COVID-19 as underlying pathology, in whom rapid diagnosis in the ED and early initiation of appropriate treatment led to full recovery. Immediate extensive work-up in patients with COVID-19 and neurological symptoms proves to be paramount for best outcome. To our knowledge this is the first case of PRES described in a patient with Delta variant of SARS-COV-2.